2020, Vol. 3, Issue 2, Part A
New approach to deep diabetic foot ulcer (DFU) treatment-potential of secretome from Wharton’s jelly mesenchymal stem cell therapy
Author(s)
Sukmawati Tansil Tan, Yohanes Firmansyah and Jessica Elizabeth
Abstract
Diabetic foot ulcer is one of the complications of chronic diabetes in the form of lesions in deep tissue and associated neurological disorders and peripheral vascular disease in the lower limbs. DFU has a significant impact on the health and quality of life of patients and their families. The effect that is often felt is ranging from pain, loss of function and mobility, depression, difficulty and anxiety, shame, social isolation, the financial burden of extended hospital stays and chronic morbidity, or even amputation to death. This case report reports the case of a 64-year-old man with DFU grade 3 and has been advised to undergo a finger amputation surgery by a surgeon to prevent infection, and the finger is predicted to be untenable. After intervention with a single dose, intracutaneous injection of Secretome from-Placental Wharton Jelly Stem Cell (SC-PWJSC), regular insulin, and control Sugar Blood Glucose. There is a very significant wound repair. Patients reported being satisfied with this treatment.
Pages: 21-26 | Views: 1744 | Downloads: 896
How to cite this article:
Sukmawati Tansil Tan, Yohanes Firmansyah, Jessica Elizabeth. New approach to deep diabetic foot ulcer (DFU) treatment-potential of secretome from Wharton’s jelly mesenchymal stem cell therapy. Int J Dermatol Venereology Leprosy Sci 2020;3(2):21-26. DOI:
10.33545/26649411.2020.v3.i2a.41
